Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design

Nucleic Acids Research

Volumn 36, Issue 15, 2008, Pages 5083-5092

  Bauman, Joseph D ^a,b   Das, Kalyan ^a,b   Ho, William C ^a,b   Baweja, Mukta ^a   Himmel, Daniel M ^a,b   Clark Jr , Arthur D ^a,b   Oren, Deena A ^a,d   Boyer, Paul L ^a   Hughes, Stephen H ^c   Shatkin, Aaron J ^a   Arnold, Eddy ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RILPIVIRINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CHEMICAL MODIFICATION; CLONING; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DESIGN; DRUG STRUCTURE; ENZYME CONFORMATION; ENZYME ENGINEERING; ENZYME STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; METHYLATED OVERLAP EXTENSION LIGATION INDEPENDENT CLONING; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ANALYSIS; X RAY ANALYSIS;

CLONING, MOLECULAR; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HIV REVERSE TRANSCRIPTASE; MODELS, MOLECULAR; MUTAGENESIS; NITRILES; PROTEIN ENGINEERING; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 50849105061     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkn464     Document Type: Article

References (31)

1. Coffin,J.M. (1995) HIV population dynamics in vivo-implications for genetic variation, pathogenesis, and therapy. Science, 267, 483-489.
2. Larder,B.A. and Kemp,S.D. (1989) Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science, 246, 1155-1158.
3. Janssen,P.A., Lewi,P.J., Arnold,E., Daeyaert,F., de Jonge,M., Heeres,J., Koymans,L., Vinkers,M., Guillemont,J., Pasquier,E. et al. (2005) In search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of 4- 4- 4-[(1E)-2-cyanoethenyl]-2, 6-dimethylphenyl]amin o]-2- pyrimidinyl]am ino]benzonitrile (R278474, rilpivirine). J. Med. Chem., 48, 1901-1909.
4. Geretti,A.M., (2008) Shifting paradigms: The resistance profile of etravirine. J. Antimicrob. Chemother. [Epub ahead of print; doi:10.1093/jac/dkn248]; June 19, 2008.
5. Das,K., Clark,A.D. Jr, Lewi,P.J., Heeres,J., de Jonge,M.R., Koymans,L.M., Vinkers,H.M., Daeyaert,F., Ludovici,D.W., Kukla,M.J. et al. (2004) Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem, 47, 2550-2560.
6. Das,K., Bauman,J.D., Clark,A.D. Jr., Frenkel,Y.V., Lewi,P.J., Shatkin,A.J., Hughes,S.H. and Arnold,E. (2008) High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations. Proc. Natl Acad. Sci. USA, 105, 1466-1471.
7. Das,K., Lewi,P.J., Hughes,S.H. and Arnold,E. (2005) Crystallography and the design of anti-AIDS drugs: Conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog. Biophys. Mol. Biol, 88, 209-231.
8. Dale,G.E., Oefner,C. and D'Arcy,A. (2003) The protein as a variable in protein crystallization. J. Struct. Biol, 142, 88-97.
9. Derewenda,Z.S. (2004) The use of recombinant methods and molecular engineering in protein crystallization. Methods, 34, 354-363.
10. Derewenda,Z.S. and Vekilov,P.G. (2006) Entropy and surface engineering in protein crystallization. Acta Crystallogr. D Biol. Crystallogr, 62, 116-124.
11. Ren,J., Esnouf,R., Garman,E., Somers,D., Ross,C., Kirby,I., Keeling,J., Darby,G., Jones,Y., Stuart,D. et al. (1995) High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol., 2, 293-302.
12. Kohlstaedt,L.A., Wang,J., Friedman,J.M., Rice,P.A. and Steitz,T.A. (1992) Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science, 256, 1783-90.
13. Ding,J., Das,K., Tantillo,C., Zhang,W., Clark,A.D. Jr., Jessen,S., Lu,X., Hsiou,Y., Jacobo-Molina,A., Andries,K. et al. (1995) Structure of HIV-1 reverse transcriptase in a complex with the nonnucleoside inhibitor alpha-APA R 95845 at 2.8 resolution. Structure, 3, 365-379.
14. Hogberg,M., Sahlberg,C., Engelhardt,P., Noreen,R., Kangasmetsa,J., Johansson,N.G., Oberg,B., Vrang,L., Zhang,H., Sahlberg,B.L. et al. (1999) Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues. J. Med. Chem., 42, 4150-4160.
15. Sarafianos,S.G., Clark,A.D. Jr., Tuske,S., Squire,C.J., Das,K., Sheng,D., Ilankumaran,P., Ramesha,A.R., Kroth,H., Sayer,J.M. et al. (2003) Trapping HIV-1 reverse transcriptase before and after translocation on DNA. J. Biol. Chem., 278, 16280-16288.
16. Donahue,W.F., Turczyk,B.M. and Jarrell,K.A. (2002) Rapid gene cloning using terminator primers and modular vectors. Nucleic Acids Res., 30, e95.
17. Clark,A.D. Jr., Jacobo-Molina,A., Clark,P., Hughes,S.H. and Arnold,E. (1995) Crystallization of human immunodeficiency virus type 1 reverse transcriptase with and without nucleic acid substrates, inhibitors, and an antibody Fab fragment. Methods Enzymol., 262, 171-185.
18. Otwinowski,Z. and Minor,W. (1997) Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods Enzymol., 276, 307-326.
19. Hsiou,Y., Ding,J., Das,K., Clark,A.D. Jr., Hughes,S.H. and Arnold,E. (1996) Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: Implications of conformational changes for polymerization and inhibition mechanisms. Structure, 4, 853-860.
20. Boyer,P.L., Sarafianos,S.G., Arnold,E. and Hughes,S.H. (2002) The M184V mutation reduces the selective excision of zidovudine 5′-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. J. Virol, 76, 3248-3256.
21. Boyer,P.L., Stenbak,C.R., Clark,P.K., Linial,M.L. and Hughes,S.H. (2004) Characterization of the polymerase and RNase H activities of human foamy virus reverse transcriptase. J. Virol, 78, 6112-6121.
22. Huang,H., Chopra,R., Verdine,G.L. and Harrison,S.C. (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science, 282, 1669-1675.
23. Huang,H., Harrison,S.C. and Verdine,G.L. (2000) Trapping of a catalytic HIV reverse transcriptase*template:pRimer complex through a disulfide bond. Chem. Biol., 7, 355-364.
24. Ho,S.N., Hunt,H.D., Horton,R.M., Pullen,J.K. and Pease,L.R. (1989) Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene, 77, 51-59.
25. Horton,R.M., Hunt,H.D., Ho,S.N., Pullen,J.K. and Pease,L.R. (1989) Engineering hybrid genes without the use of restriction enzymes: Gene splicing by overlap extension. Gene, 77, 61-68.
26. Chan,J.H., Hong,J.S., Hunter,R.N., Orr,G.F., Cowan,J.R. 3rd, Sherman,D.B., Sparks,S.M., Reitter,B.E., Andrews,C.W., Hazen,R.J. et al. (2001) 2-Amino-6-arylsulfonylbenzonitriles as nonnucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem, 44, 1866-1882.
27. Rodgers,D.W., Gamblin,S.J., Harris,B.A., Ray,S., Culp,J.S., Hellmig,B., Woolf,D.J., Debouck,C. and Harrison,S.C. (1995) The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl Acad. Sci.USA, 92, 1222-1226.
28. Budihas,S.R., Gorshkova,I., Gaidamakov,S., Wamiru,A., Bona,M.K., Parniak,M.A., Crouch,R.J., McMahon,J.B., Beutler,J.A. and Le Grice,S.F. (2005) Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. Nucleic Acids Res., 33, 1249-1256.
29. Hartshorn,M.J., Murray,C.W., Cleasby,A., Frederickson,M., Tickle,I.J. and Jhoti,H. (2005) Fragment-based lead discovery using X-ray crystallography. J. Med. Chem., 48, 403-413.
30. Bosch,J., Robien,M.A., Mehlin,C., Boni,E., Riechers,A., Buckner,F.S., Van Voorhis,W.C., Myler,P.J., Worthey,E.A., DeTitta,G. et al. (2006) Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. J. Med. Chem., 49, 5939-5946.
31. Esnouf,R.M., Ren,J., Garman,E.F., Somers,D.O., Ross,C.K., Jones,E.Y., Stammers,D.K. and Stuart,D.I. (1998) Continuous and discontinuous changes in the unit cell of HIV-1 reverse transcriptase crystals on dehydration. Acta Crystallogr. D Biol. Crystallogr., 54, 938-953.